Fluphenazine decanoate is indicated for the management of manifestations of psychotic disorders, such as schizophrenia.

Schizophrenia

• Fluphenazine Decanoate Injection may be given IM or SC. A dry syringe and needle of at least 21 gauge should be used. Use of a wet needle or syringe may cause the solution to become cloudy.
• For most patients, a dose of 12.5 to 25 mg (0.5 to 1 mL) may be given to initiate therapy.
• Appropriate dosage of Fluphenazine Decanoate Injection should be individualized for each patient and responses carefully monitored

Adverse reactions associated with fluphenazine are listed below in decreasing order of frequency:

• Extrapyramidal Symptoms (e.g., tremors, rigidity, bradykinesia)
• Drowsiness
• Insomnia
• Dizziness
• Tardive Dyskinesia
• Neuroleptic Malignant Syndrome (rare but serious)
• Hypotension
• Anticholinergic Effects (e.g., dry mouth, blurred vision)
• Weight Gain
• Hyperprolactinemia

Extrapyramidal Symptoms (EPS)

Insomnia (Difficulty in Falling asleep)

Tardive Dyskinesia

Weight Gain

• Extrapyramidal Symptoms (EPS): Monitor for EPS, especially during the initial phase of treatment. Use caution in patients with a history of seizures.
• Tardive Dyskinesia: Consider the risk of tardive dyskinesia, particularly with long-term use. If symptoms appear, consider dose reduction or discontinuation.
• Neuroleptic Malignant Syndrome (NMS): NMS is a potentially fatal condition associated with antipsychotic use. Discontinue treatment if NMS occurs and provide supportive care.
• QT Prolongation: Use caution in patients with a history of QT prolongation or other conditions predisposing to arrhythmias.
• Hyperglycemia and Diabetes Mellitus: Monitor glucose levels in patients with pre-existing diabetes or risk factors for diabetes.
• Hypotension: Monitor blood pressure during the initial phase of treatment, especially in elderly patients.